

Liflow[®]: an innovative AI-enhanced solution to optimize oncology follow-up

Montpellier, France, April 16, 2024, at 5:45 pm CET

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian[®] and Liflow[®], announces the regulatory submission of its Liflow[®] 1.0 solution (registered trademark of the Myra project), an oncology platform dedicated to the analysis of diagnostic imaging and cancer follow-up.

An intelligent platform dedicated to longitudinal follow-up in oncology

Cancer is a major public health issue, with new cases expected to increase by over 47% between now and 2040¹. Against this backdrop, Liflow[®], a platform for diagnosis and longitudinal follow-up in oncology, provides radiologists with a set of clinical tools addressing all aspects of cancer patient follow-up.

Liflow[®] represents a paradigm shift in oncology software solutions, with artificial intelligence algorithms integrated into a single tool, optimizing the power of technology in the service of medicine. In this way, Liflow[®] supports the radiologist's analysis in terms of efficiency and diagnostic performance and provides a high level of interpretation comfort through a unified interface. The solution natively integrates multi-organ AI algorithms dedicated to the liver and lungs, developed by Guerbet and MeVis Medical Solutions AG. By automatically calculating the evolution of lesions, Liflow[®] optimizes their detection and facilitates medical reporting. Rigorously evaluated in a number of clinical trials, Guerbet's AI Liver has demonstrated its performance at the Angers University Hospital, the Beaujon Hospital (APHP)² and the Kyoto University Hospital³.

Liflow[®] marketing to begin in 2024

Since raising €4.9 million to launch the project in 2021, Liflow[®] has achieved a few decisive development milestones. At the end of 2022, the first prototype was successfully tested in collaboration with the Montpellier Cancer Institute (ICM), validating the platform's innovative functionalities and at the end of 2023, a first prototype version natively integrating AI was finalized. Liflow[®], a subscription-based Cloud solution, was developed in collaboration with radiologists from the I-SERIS Group, the ICM and Angers University Hospital.

¹ GLOBOCAN 2020 study

² Deep-learning algorithm for the detection of colorectal cancer liver metastases: comparison with radiology (R. Sartoris) JFR 2023

³ Phase II study at Kyoto University. Publication Eur. Jour. Rad. June 2023

Throughout development, these partners tested the solution and provided valuable feedback, enabling Intrasense to adapt the platform to the real needs of healthcare professionals.

The first version of the solution was submitted for CE marking under MDR on April 12, 2024, with a marketing target of the second half of 2024. Intrasense will continue to enhance its Liflow® solution thanks to feedback from radiologist partners and will carry out its first deployments at partner sites.

Intrasense and Guerbet share an ambitious business plan and functional roadmap for the platform over the coming years, with the aim of making it a global benchmark solution in oncology.

First presentation on the French market

Liflow® was previewed at the annual Unicancer Imaging Days, held in Nice (France) on April 4 and 5. Unicancer, the French hospital network dedicated to the fight against cancer, represents 22 hospital sites and over 23,000 healthcare professionals. Bringing together the heads of imaging departments from Unicancer establishments, this event was an opportunity for Intrasense to share Liflow® innovations with a reference network for cancer follow-up.

Intrasense is also strengthening its sales teams to prepare for the commercialization of Liflow® and support its growth strategy.

« The upcoming launch of Liflow® represents a decisive step in our growth strategy. By offering new and increasingly innovative solutions, we are demonstrating our commitment to pushing back the boundaries of oncology imaging. Liflow® represents our determination to improve oncology healthcare, offering added value to our customers and the medical community » says **Nicolas Reymond, Intrasense CEO.**

About d'Intrasense

French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced visualization solution for radiology, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow®, a new platform

dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up.

A Guerbet Group subsidiary since June 2023, Intrasense continues to enhance its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

Learn more at www.intrasense.fr

Intrasense

Salomé Sylvestre

Communications officer

Phone: +334 67 13 01 30

investisseurs@intrasense.fr

NewCap

Thomas Grojean

Financial Communication
and investor relations

Phone: +331 44 71 20 40

intrasense@newcap.eu